Award
NIH Reporter #5R01FD007837-02
A Randomized Study of Maternal Donor Derived CMV Cytotoxic T-Lymphocytes (CTLs) and Valganciclovir vs Valganciclovir in Neonates With Moderate/Severe Maternal Acquired CMV Infection
Recipient
Not specified
Award Amount
$324,998.00
Ceiling
$324,998.00
Awarded
September 02, 2025
Identifier
5R01FD007837-02
Federal grant awarded by the FDA for a clinical trial studying immune cell therapy in neonates with maternal acquired CMV infection.
Description
This is a federal grant opportunity for a clinical research project on CMV in neonates, funded by the FDA, with a focus on immune cell therapy. The project involves a clinical trial for CMV infection in neonates, manufacturing under GMP conditions, and extensive immunological studies.